Joule Unlimited, Inc.

Joule Biotechnologies Names Bill Sims President and CEO

Joule Biotechnologies Names Bill Sims President and CEO

July 27, 2009

Cambridge, Mass.—July 27, 2009—Joule Biotechnologies, Inc., an innovative bioengineering startup developing game-changing alternative energy solutions, today announced the appointment of Bill Sims as president and CEO. Sims brings nearly 30 years of experience growing both emerging and established companies across multiple technology and product sectors. In addition to his new position, he will continue to serve on the company’s board of directors.

Mascoma Corporation

Mascoma Announces Feedstock Processing and Lignin Supply Agreement with Chevron Technology Ventures

Mascoma Announces Feedstock Processing and Lignin Supply Agreement with Chevron Technology Ventures

September 14, 2009

 Lebanon, New Hampshire – September 14, 2009 – Mascoma Corporation today announced that it has entered into a feedstock processing and lignin supply agreement with Chevron Technology Ventures (CTV), a division of Chevron U.S.A., Inc.

Under terms of the agreement, CTV will provide various sources of lignocellulosic feedstock to Mascoma. Mascoma will then convert the feedstock to cellulosic ethanol through its proprietary process, which produces lignin as a by-product. Mascoma will provide this lignin to CTV for evaluation.

VisEn Medical, Inc.

VisEn Launches New Cat B 680 FAST™ Fluorescence Molecular Imaging Agent

VisEn Launches New Cat B 680 FAST™ Fluorescence Molecular Imaging Agent

January 19, 2010

Extends VisEn’s Leading Fluorescence Molecular Imaging Agent Portfolio to Enable Expanded Readouts of Key Protease Biomarkers in Research and Drug Development

BEDFORD, MA (January 19, 2010)—VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new Cat B 680 FAST™ imaging agent for measuring and monitoring cathepsin B activity associated with disease progression and therapeutic response in vivo.

Receptos, Inc.

Receptos Initiates Clinical Trials for S1P1 Agonist Program, Aimed at Multiple Sclerosis

Receptos Initiates Clinical Trials for S1P1 Agonist Program, Aimed at Multiple Sclerosis

January 27, 2011

First subject dosed in Phase 1 Single Ascending and Multiple Ascending Dose Safety Study

Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Enters Into a Cooperative Research and Development Agreement with Walter Reed Army Institute of Research to Evaluate Neuroprotective Drug Compound

Concert Pharmaceuticals Enters Into a Cooperative Research and Development Agreement with Walter Reed Army Institute of Research to Evaluate Neuroprotective Drug Compound

February 2, 2011

Advances Concert’s R&D for Novel Drugs to Treat Seizure-Generating Diseases and Injuries

Pervasis Therapeutics, Inc.

Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence

Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence

January 19, 2011

Bolstered by Landmark Research and Multiple Preclinical Studies, Groundbreaking Therapy Holds Promise to Deliver Safe, Effective Cell Therapy Treatment for Solid Tumors

Joule Unlimited, Inc.

Joule Elects Former White House Chief of Staff John Podesta to Board of Directors

Joule Elects Former White House Chief of Staff John Podesta to Board of Directors

January 18, 2011

Cambridge, Mass. –January 18, 2010 – Joule Unlimited, Inc., pioneer of Liquid Fuel from the Sun™, today announced the election of John Podesta to its board of directors. A veteran of two White House administrations, Mr. Podesta will bring considerable expertise to Joule in the realm of public policy as well as partnering with the public sector.

BG Medicine, Inc.

BG Medicine Announces Nationwide Availability of Galectin-3 Testing Service through LabCorp

BG Medicine Announces Nationwide Availability of Galectin-3 Testing Service through LabCorp

January 18, 2011

WALTHAM, Mass.--(BUSINESS WIRE)--BG Medicine announced today that Laboratory Corporation of America® Holdings (LabCorp®)now offers galectin-3 testing services using the BGM Galectin-3 test for heart failure. The BGM Galectin-3 test was cleared by the FDA in November 2010 as an aid in assessing the prognosis of patients with chronic heart failure. Elevated galectin-3 levels are associated with an inherently progressive form of heart failure that is associated with an increased risk of hospitalization or death.

Mascoma Corporation

Mascoma, Frontier Renewable Resources and Valero Ink Deal to Develop Commercial Cellulosic Ethanol Biorefinery

Mascoma, Frontier Renewable Resources and Valero Ink Deal to Develop Commercial Cellulosic Ethanol Biorefinery

January 13, 2011

Valero invests in Mascoma and signs a letter of intent to help pave way for Kinross, Michiganbased biorefinery.

Mascoma Corporation

Valero to Invest in Ethanol Plant

Valero to Invest in Ethanol Plant

January 13, 2011

The Wall Street Journal previewed the recently announced agreement to between Flagship portfolio company Mascoma and Valero Energy Corp., citing it as a sign of the maturing cellulosic-ethanol technology and market.